TrialDrug design, development and therapy2015

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin.

Jin Ah Jung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.